Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer

Recruiting now

Conditions studied: Metastatic Castration Resistant Prostate Cancer

In brief

The purpose of this study is to describe routine clinical practice with lutetium (177Lu) vipivotide tetraxetan on Health related quality of life (HRQoL) at baseline, on treatment, and post progression.

Key facts

Study ID

NCT06517719

Run by

Novartis Pharmaceuticals

People needed

500

Starts

2024-09-04

Expected to finish

2028-02-01

Last updated by the study team

2026-07-13

Who can join

Age: 18 and older, up to 99. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• All patients must meet the following inclusion criteria during the identification period:
• Adult male patients diagnosed with mCRPC and initiating lutetium (177Lu) vipivotide tetraxetan by treating physician as per local label. After treatment decision enrollment is allowed before date of cycle 1 or within 2 weeks after the date of Cycle 1.
• ≥ 18 years old at the time of enrollment
• Written informed consent must be obtained prior to any data collection
• Willing to participate in Quality of Life post treatment date collection for 1 year

You may not qualify if…

• Patients must not meet the following exclusion criterion during the identification period:
• Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with lutetium (177Lu) vipivotide tetraxetan

Where it is running

• Novartis Investigative Site — Konstanz, Baden-Wurttemberg, Germany (enrolling)
• Novartis Investigative Site — Stuttgart, Baden-Wurttemberg, Germany (enrolling)
• Novartis Investigative Site — Munich, Bavaria, Germany (enrolling)
• Novartis Investigative Site — Regensburg, Bavaria, Germany (enrolling)
• Novartis Investigative Site — Würzburg, Bavaria, Germany (enrolling)
• Novartis Investigative Site — Cottbus, Brandenburg, Germany (enrolling)
• Novartis Investigative Site — Frankfurt (Oder), Brandenburg, Germany (enrolling)
• Novartis Investigative Site — Ludwigshafen, Germany, Germany (enrolling)
• Novartis Investigative Site — Marburg, Hesse, Germany (enrolling)
• Novartis Investigative Site — Cologne, North Rhine-Westphalia, Germany (enrolling)
• Novartis Investigative Site — Dresden, Saxony, Germany (enrolling)
• Novartis Investigative Site — Leipzig, Saxony, Germany (enrolling)
• Novartis Investigative Site — Halle, Saxony-Anhalt, Germany (enrolling)
• Novartis Investigative Site — Jena, Thuringia, Germany (enrolling)
• Novartis Investigative Site — Aachen, Germany (enrolling)
• Novartis Investigative Site — Augsburg, Germany (enrolling)
• Novartis Investigative Site — Berlin, Germany (enrolling)
• Novartis Investigative Site — Berlin, Germany (enrolling)
• Novartis Investigative Site — Berlin, Germany (enrolling)
• Novartis Investigative Site — Bielefeld, Germany (enrolling)
• Novartis Investigative Site — Bonn, Germany (enrolling)
• Novartis Investigative Site — Braunschweig, Germany (enrolling)
• Novartis Investigative Site — Chemnitz, Germany (enrolling)
• Novartis Investigative Site — Dortmund, Germany (enrolling)
• Novartis Investigative Site — Dortmund, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.